Treatment may lower long-term organ damage risk in congenital TTP
Study authors stress findings are hypothesis-generating predictions
Written by |
Regular preventive treatment with the approved infusion therapy Adzynma (ADAMTS13 recombinant-krhn) may help reduce the long-term risk of organ damage in people with congenital thrombotic thrombocytopenic purpura (TTP), according to a study.
Based on predictions from six U.K. clinicians experienced in treating the rare bleeding disorder, researchers estimated that fewer than 8% of patients receiving regular preventive treatment with Adzynma would develop serious complications affecting the brain, heart, or kidneys over periods of up to 17 years.
“These expert-derived estimates provide structured insights into potential long-term outcomes associated with [Adzynma] prophylaxis, which can inform future research, health technology assessments, and evidence-generation efforts in [congenital TTP],” researchers wrote.
However, the estimates reflect expert predictions rather than observed patient outcomes and therefore “remain hypothesis-generating,” the team cautioned. “Prospective empirical studies are required to confirm the findings.”
The study, “Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study,” was published in Advances in Therapy. It was funded by Takeda, the company that markets Adzynma. Two of the study’s eight authors are Takeda employees, and two are former employees.
Adzynma delivers a functional version of key enzyme
TTP is marked by a deficiency of ADAMTS13, an enzyme that helps prevent excessive blood clotting. Its congenital form is caused by mutations in the gene that provides instructions for making the enzyme. Without enough ADAMTS13, tiny blood clots can form throughout the body, blocking blood flow and potentially damaging organs, particularly the brain, heart, and kidneys.
For years, preventive treatment for congenital TTP has relied on plasma-based therapies, including regular infusions of fresh frozen plasma. Plasma is the noncellular portion of blood that contains several proteins and enzymes, including ADAMTS13. Administering these therapies can help replenish the missing enzyme to control TTP symptoms. However, patients can still develop long-term organ damage.
Adzynma, given via an injection into the bloodstream, delivers a functional version of ADAMTS13 to the body. Approved for congenital TTP in the U.S. and other regions, it is now favored over plasma-based therapies for preventive treatment in patients who are in remission, according to current guidelines.
Although a Phase 3 trial (NCT03393975) found that no acute or subacute TTP episodes occurred during approximately one year of Adzynma treatment, the “long-term impact of [Adzynma] prophylaxis on renal, cardiac, and neurological outcomes remains unknown,” the researchers wrote.
Clinician emphasized value of early, continuous treatment
To help address this gap, researchers asked six U.K. clinicians experienced in treating congenital TTP to draw on their medical knowledge and experience to predict the long-term risk of organ damage in patients receiving regular Adzynma treatment.
The clinicians considered hypothetical children, adolescents, and adults who had completed the Adzynma Phase 3 trial, had no previous organ damage, and continued receiving Adzynma. The predictions began at mean ages of 9.1 for children and adolescents and 38.3 for adults, reflecting the mean ages of participants in each group at trial completion.
From those starting ages, clinicians estimated the likelihood of developing at least one serious complication — stroke, transient ischemic attack (a temporary interruption of blood flow to the brain), heart attack, or chronic kidney disease — as patients grew older. The researchers then combined their individual estimates to calculate the projected risk of organ damage at different ages.
For children and adolescents, the estimated risk was 3.25% by age 15, rising to 4.48% by age 20 and 5.76% by age 25. These figures were lower than historical estimates calculated using data from a 2022 study of patients receiving plasma-based therapies.
Expert-elicited estimates suggest that long-term organ damage risks may be lower with continuous [Adzynma] prophylaxis than benchmark estimates for [plasma-based therapy] across age groups.
A similar pattern emerged for adults. With continued Adzynma treatment, the predicted risk was 4.85% by age 45 and 7.42% by age 55. The corresponding historical estimates for plasma-based therapies were 11.4% and 25.5%.
The clinicians emphasized that starting preventive treatment early and receiving it consistently could help limit organ damage over time.
“Expert-elicited estimates suggest that long-term organ damage risks may be lower with continuous [Adzynma] prophylaxis than benchmark estimates for [plasma-based therapy] across age groups,” the researchers wrote.
However, they cautioned that “no direct comparative analysis was conducted,” meaning the findings cannot establish whether Adzynma offers greater protection than preventive plasma-based therapy.
Still, “these hypothesis-generating findings can help inform clinical decision-making and support health technology assessments, while highlighting the importance of sustained prophylaxis and treatment adherence,” the team concluded.

Leave a comment
Fill in the required fields to post. Your email address will not be published.